Table 2.
Univariate and multivariate analysis of prognostic factors for progression-free (PFS) and overall survival (OS)
| PFS | OS | |||||
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Univariate analysis | ||||||
| Age, ≥70 | 2.83 | 1.00 to 7.98 | 0.049 | 2.58 | 0.79 to 8.44 | 0.12 |
| ECOG-PS, 1–2 | 1.39 | 0.57 to 3.39 | 0.46 | 3.11 | 0.95 to 10.16 | 0.061 |
| Number of previous regimens, ≥2 | 1.56 | 0.62 to 3.93 | 0.35 | 1.43 | 0.43 to 4.71 | 0.56 |
| Stage, IV or recurrence | 0.75 | 0.21 to 2.62 | 0.65 | 0.49 | 0.13 to 1.84 | 0.29 |
| Histology, adenocarcinoma | 1.03 | 0.41 to 2.60 | 0.95 | 0.48 | 0.16 to 1.43 | 0.19 |
| TPS, <1% | 1.83 | 0.66 to 5.09 | 0.25 | 1.89 | 0.56 to 6.40 | 0.31 |
| ΔTLG+ΔADCmean, ≥16.5 | 37.72 | 4.50 to 316.2 | 0.00082 | 9.29 | 2.49 to 34.62 | 0.00091 |
| Multivariate analysis | ||||||
| ΔTLG+ΔADCmean, ≥16.5 | 37.72 | 4.50 to 316.2 | 0.00082 | |||
ADC, apparent diffusion coefficient; ECOG-PS, Eastern Cooperative Oncology Group performance status; TLG, total lesion glycolysis; TPS, tumor proportion score.